Skip to Main Content

We’re in a new phase of the Covid-19 pandemic in which new mutations will have to be consistently monitored — especially as the vaccine race continues. This reality is something I’m always thinking about in my role in financial services supporting health care clients at J.P. Morgan.

How will these mutations affect the business of health care — and how can clients and organizations best prepare — for next month and for the years to come? And how are health care business leaders supposed to model and implement strategies when there exists such a wide range of potential outcomes stemming from new virus variants?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment